ATAI ATAI LIFE SCIENCES BV

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. Details of the company’s participation:

Format: Fireside chat and 1x1 investor meetings

Date and Time: Fireside chat on Thursday, November 20 at 11:30 A.M. GMT/ 6:30 A.M. ET

Webcast link:

An archived replay will be available on the Investors section of the AtaiBeckley website under for up to 90 days.

About Atai Beckley N.V.

AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments. It was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit or follow the Company on and on .

Contact Information

Investor Contact:

Media Contact:



EN
13/11/2025

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Add...

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fundExpands market presence across the S&P Total Market Index, covering virtually all U.S.-listed equities, and the S&P Completion Index, which represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500®Continues a series of index inclusions acr...

March 24, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treat...

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the peer-reviewed publication of results from its ongoing four-part Phase 2a study () evaluating BPL-003 (mebu...

March 17, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Succ...

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts from both parallel Phase 3 pivotal studiesCommercial readiness advancing with scalable treatment model aligned to existing interventional psychiatry workflowsContinued pipeline progress, including positive Phase 2a results for ...

March 10, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Result...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measuresCash run...

March 6, 2026 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in...

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for Q2 2026BPL-003 was previously granted Breakthrough Therapy designation by the FDA for treatment-resistant depressionVirtual Investor Day scheduled on March 6, 2026, to provide further detail on the BPL-003 Phase 3 clinical strategy NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley In...

March 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch